Literature DB >> 8898632

Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease.

M F Vaezi1, J E Richter.   

Abstract

BACKGROUND & AIMS: Acid and pepsin are known to cause esophagitis. However, the role of duodenogastroesophageal reflux (DGER) in producing esophageal mucosal injury across the spectrum of gastroesophageal reflux disease (GERD) is controversial.
METHODS: Twenty controls (13 men; mean age, 41 years), 30 patients with GERD (15 men; mean age, 41 years), and 20 patients with Barrett's esophagus (17 men; mean age, 58 years) were studied. Twenty-four-hour ambulatory acid and bilirubin measurements were obtained with Bilitec 2000 using a glass pH electrode and fiberoptic sensor.
RESULTS: Percentage times pH was < 4, bilirubin level was > or = 0.14, and fasting gastric bile acid concentrations showed a graded increase across the GERD spectrum. Esophageal exposure to both acid and DGER was the most prevalent reflux pattern (100% in patients with complicated and 89% in patients with uncomplicated Barrett's esophagus, 79% in patients with esophagitis, and 50% in patients without esophagitis). The majority (70%-91%) of DGER episodes occurred in an acidic environment (pH < 4). Linear regression analysis found a significant correlation (r = 0.73; P < 0.01) between percentage time pH was < 4 and percentage time bilirubin absorbance level was > or = 0.14.
CONCLUSIONS: Both acid and DGER show a graded increase in severity across the GERD spectrum. Acid and DGER occur simultaneously in the majority of the reflux episodes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898632     DOI: 10.1053/gast.1996.v111.pm8898632

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  125 in total

1.  Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?

Authors:  E S Bonapace; R S Fisher; H P Parkman
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

2.  Proton pump inhibitors for Barrett's oesophagus.

Authors:  G Triadafilopoulos
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

3.  The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum.

Authors:  R C Fitzgerald; M J Farthing
Journal:  Curr Gastroenterol Rep       Date:  2000-12

4.  A review of reflux esophagitis around the world.

Authors:  Edwin J Zarling
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

5.  Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Joaquín Molina; Juan Bermejo; Manuel Canteras
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

Review 6.  Functional heartburn: the stimulus, the pain, and the brain.

Authors:  R Fass; G Tougas
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

7.  Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells.

Authors:  Xiaofang Huo; Stefanie Juergens; Xi Zhang; Davood Rezaei; Chunhua Yu; Eric D Strauch; Jian-Ying Wang; Edaire Cheng; Frank Meyer; David H Wang; Qiuyang Zhang; Stuart J Spechler; Rhonda F Souza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-02       Impact factor: 4.052

8.  Oesophageal clearance of acid and bile: a combined radionuclide, pH, and Bilitec study.

Authors:  G H Koek; R Vos; P Flamen; D Sifrim; F Lammert; B Vanbilloen; J Janssens; J Tack
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Composite score of reflux symptoms in diagnosis of gastroesophageal reflux disease.

Authors:  Jin-Hai Wang; Jin-Yan Luo; Lei Dong; Jun Gong; Ai-Li Zuo
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

10.  Role of bile acids, prostaglandins and COX inhibitors in chronic esophagitis in a mouse model.

Authors:  C Poplawski; D Sosnowski; A Szaflarska-Popławska; J Sarosiek; R McCallum; Z Bartuzi
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.